Cargando…
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy /
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press,
[2019]
|
| Edición: | First edition. |
| Colección: | Cancer sensitizing agents for chemotherapy ;
v. 5. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1088892218 | ||
| 003 | OCoLC | ||
| 005 | 20231120010342.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 190301s2019 enk ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d OPELS |d EBLCP |d UAB |d UKMGB |d MERER |d UKAHL |d OCLCF |d STF |d ESU |d UWO |d DCT |d YDX |d OCLCQ |d CASUM |d AUD |d OCLCA |d OCLCQ |d S2H |d OCLCO |d LVT |d UX1 |d VT2 |d OCLCO |d OCLCA |d OCLCQ |d OCLCO |d COM |d OCLCO |d OCL |d OCLCQ |d OCLCO | ||
| 066 | |c (S | ||
| 015 | |a GBB946582 |2 bnb | ||
| 016 | 7 | |a 019278673 |2 Uk | |
| 016 | 7 | |a 101746351 |2 DNLM | |
| 019 | |a 1089005749 |a 1141460999 |a 1229732913 |a 1235827078 |a 1244447859 | ||
| 020 | |a 9780128176627 |q (electronic bk.) | ||
| 020 | |a 0128176628 |q (electronic bk.) | ||
| 020 | |z 9780128176610 | ||
| 020 | |z 012817661X | ||
| 035 | |a (OCoLC)1088892218 |z (OCoLC)1089005749 |z (OCoLC)1141460999 |z (OCoLC)1229732913 |z (OCoLC)1235827078 |z (OCoLC)1244447859 | ||
| 050 | 4 | |a RC280.P25 | |
| 060 | 4 | |a 2019 D-083 | |
| 060 | 4 | |a WI 810 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.99437 |2 23 |
| 100 | 1 | |a Nagaraju, Ganji Purnachandra, |e author. | |
| 245 | 1 | 0 | |a Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy / |c Ganji Purnachandra Nagaraju. |
| 250 | |a First edition. | ||
| 264 | 1 | |a London : |b Academic Press, |c [2019] | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Cancer sensitizing agents for chemotherapy ; |v volume 5 | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed March 4, 2019). | |
| 505 | 0 | |a Front Cover; Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy; Copyright; Dedication; Contents; Contributors; About the Editor; About the Series Editor; Aims and Scope for Series ""Cancer Sensitizing Agents for Chemotherapy; Preface; Chapter 1: Overview of Pancreatic Cancer Biology; Introduction; Pathogenesis and Molecular Biology; Three Biological Stages of Cancer Development; Initiation; Clonal Expansion; Oncogenesis; KRAS; Raf/Mitogen-Activated Protein Kinase (MAPK) Cascade; Phosphoinositide 3-Kinase/ATK Cascade; Nuclear Factor Kappa B Signaling Cascade | |
| 505 | 8 | |a Tumor Suppressor GenesCDKN2A; TP53; SMAD4; Introduction to Local and Distant Microenvironments; Familial Pancreatic Cancers; Conclusions; References; Further Reading; Chapter 2: Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender; Introduction; Pancreatic Cancer Incidences and Prognosis: Association of Age and Gender; Chemoresistance: Association With Age and Gender; Mechanisms Associated With Chemoresistance; Factors Modulated in Various Age Groups; Conclusion; Acknowledgments; References; Chapter 3: EMT Contributes to Chemoresistance in Pancreatic Cancer; Introduction | |
| 505 | 8 | |a Gemcitabine SensitivityGemcitabine and Chemoresistance; Role of Gemcitabine in Targeting Signaling Pathways; Conclusion; Acknowledgment; References; Chapter 5: Pancreatic Cancer and Possible Therapeutic Options; Introduction; Reasons Behind the Above Statistics?; Brief Outline of Treatment; Tumor-Node-Metastasis Staging and Clinical Classification; Modalities for Evaluating TNM Staging; Clinical Classification; Treatment Options for Pancreatic Adenocarcinoma; Localized Surgically Resectable Stage I and II Disease; Adjuvant Therapy; Gemcitabine and 5-Fluorouracil; Gemcitabine and S-1 | |
| 505 | 8 | |a Gemcitabine and CapecitabineAdjuvant Chemoradiation; Gemcitabine Plus Nab-Paclitaxel; Neoadjuvant Therapy; Adjuvant Therapy in Borderline Removable Pancreatic Carcinoma; Evidence Supporting Neoadjuvant Therapy; FOLFIRINOX as Neoadjuvant Therapy; NAC-GSL (Neoadjuvant Chemotherapy-Gemcitabine, S-1, LV); Metastatic Pancreatic Cancer: Treatment Options; Early Period; First-Line Therapies; FOLFIRINOX; PRODIGE-4/ACCORD-11 Trial; Outcomes of PRODIGE-4/ACCORD-11 Trial; Precautionary and Toxicity Reducing Strategies; Gemcitabine Plus Nab-Paclitaxel; The MPACT Trial | |
| 650 | 0 | |a Pancreas |x Cancer. | |
| 650 | 0 | |a Chemotherapy. | |
| 650 | 0 | |a Drug resistance in cancer cells. | |
| 650 | 1 | 2 | |a Drug Resistance, Neoplasm |0 (DNLM)D019008 |
| 650 | 1 | 2 | |a Pancreatic Neoplasms |x drug therapy |0 (DNLM)D010190Q000188 |
| 650 | 2 | |a Drug Therapy |0 (DNLM)D004358 | |
| 650 | 2 | |a Pancreatic Neoplasms |0 (DNLM)D010190 | |
| 650 | 6 | |a Pancr�eas |x Cancer. |0 (CaQQLa)201-0288909 | |
| 650 | 6 | |a Chimioth�erapie. |0 (CaQQLa)201-0034750 | |
| 650 | 6 | |a Cellules canc�ereuses |x R�esistance aux m�edicaments. |0 (CaQQLa)201-0217335 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Drug resistance in cancer cells |2 fast |0 (OCoLC)fst00898703 | |
| 650 | 7 | |a Chemotherapy |2 fast |0 (OCoLC)fst00853595 | |
| 650 | 7 | |a Pancreas |x Cancer |2 fast |0 (OCoLC)fst01051974 | |
| 655 | 4 | |a Internet Resources. | |
| 776 | 0 | 8 | |i Print version: |a Nagaraju, Ganji Purnachandra. |t Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. |b First edition. |d London : Academic Press, [2019] |z 012817661X |z 9780128176610 |w (OCoLC)1078568704 |
| 830 | 0 | |a Cancer sensitizing agents for chemotherapy ; |v v. 5. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128176610 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/book/9780128176610 |z Texto completo |
| 880 | 8 | |6 505-00/(S |a Pancreatic Cancer MetastasisEMT Regulation in Pancreatic Cancers; ZEB1; SNAIL; Twist; PRRX1 (Paired Related Homeobox 1); Signaling Pathways Involved in the Regulation of EMT; TGF-β; Wnt/β-catenin; Notch; TNF-α; EMT in Chemoresistance in Pancreatic Cancer; 5-Flurouracil Chemoresistance; Gemcitabine Chemoresistance; Role of EMT in Gemcitabine Resistance; Promising Ways to Improving Gemcitabine Efficacy; Conclusions and Future Perspectives; Acknowledgments; References; Chapter 4: Pancreatic Cancer Resistance to Gemcitabine; Introduction; Gemcitabine Structure and Mechanism | |